Navigation Links
Stemedica Enters into a Global Distribution Agreement with Life Technologies
Date:6/13/2013

San Diego, CA (PRWEB) June 13, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedica’s ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally. Stemedica stem cell lines will be sold under the brand name Gibco® and will be available to purchase for research initiatives beginning Q2, 2013. The label will also carry the name of Stemedica as the manufacturer of the cell lines.

Life Technologies is a global biotechnology company with customers in more than 180 countries, providing more than 50,000 end-to-end solutions for customers in the fields of scientific research, genetic analysis and applied sciences. The Company’s systems, reagents and consumables represent some of the most cited brands in scientific research. Life Technologies employs approximately 10,000 people and upholds its ongoing commitment to innovation with more than 5,000 patents and exclusive licenses. The Company had sales of $3.8 billion in 2012.

“We are honored to be associated with a company of the caliber of Life Technologies.” stated Maynard Howe, PhD, CEO and Vice Chairman of Stemedica. “The goal of our collaboration is to serve the worldwide market of corporate research and academic institutions. Providing multiple stem cell products using a patented large-scale Reduced Oxygen Tension manufacturing process (Patent #8,420,394) to scientists who are conducting or plan to conduct stem cell research will accelerate new discoveries and ultimately enable physicians to treat medical conditions and diseases for which there are no effective treatments.”

According to Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica, “This collaboration between Stemedica and Life Technologies creates a unique opportunity for all researchers and scientists around the world to advance their discoveries. This acceleration is possible because Stemedica’s stem cell products are manufactured under controlled cGMP conditions allowing for uniform reproducibly manufactured cells to support controlled research.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarct, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information, please contact Dave McGuigan at dmcguigan (at) stemedica (dot com).

Read the full story at http://www.prweb.com/releases/stemedica-itmsc-itnsc/life-technologies/prweb10829195.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
2. Stemedica Forms Cardiology Division. Sergey Sikora, PhD Appointed As Division President
3. Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board
4. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
5. Higher medical home performance rating of community health centers linked with higher operating cost
6. Feinstein Institute to Receive Grant from Centers for Medicare & Medicaid Services to Improve Schizophrenia Treatment
7. Innokin Leo Pro Enters Russia E Cigarette Market
8. Rising Solar Engineering and Design Firm Enters 1.7 MW's in Connecticut ZREC Auction and Positions for Future Growth
9. GSA welcomes National Hartford Centers of Gerontological Nursing Excellence
10. Community health centers compare well with private practices, Stanford researcher finds
11. Allergies May Plague Renters More Than Homeowners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer Camp will be directed ... university coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. ... ages 5-13, and high school players. Session dates are as follows: , Youth Day ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away ... month of May. To date, the Lung Institute has treated over 2,000 people at their ... testament to the success of this treatment and to the patients who refuse to give ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... across 154 pages, profiling 09 key companies and ... a professional and in-depth study on the current ... basic overview of the industry including definitions, classifications, ... market analysis is provided for the international market ...
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
Breaking Medicine Technology: